Ultragenyx Pharmaceutical (RARE) Operating Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Operating Expenses data on file, last reported at $305.0 million in Q1 2026.

• Quarterly Operating Expenses rose 8.16% year-over-year to $305.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 11.5% YoY) and the FY2025 annual result came in at $1.2 billion, up 10.22% from the prior year.
• Operating Expenses fell to $305.0 million in Q1 2026 per RARE's latest filing, from $320.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $330.8 million in Q3 2025 and bottomed at $216.6 million in Q1 2022.
• The 5-year median for Operating Expenses is $271.5 million (2024), against an average of $272.0 million.
• The widest annual swing landed in 2022, when Operating Expenses soared 84.15%; it then declined 23.0% in 2023.
• Tracing RARE's Operating Expenses over 5 years: stood at $249.0 million in 2022, then grew by 0.0% to $249.0 million in 2023, then climbed by 15.25% to $287.0 million in 2024, then gained by 11.71% to $320.6 million in 2025, then decreased by 4.85% to $305.0 million in 2026.
• Per Business Quant, the three latest RARE Operating Expenses figures stand at $305.0 million (Q1 2026), $320.6 million (Q4 2025), and $330.8 million (Q3 2025).

Peer Comparison